Sugi Predict

Sugi Predict / Compounds / SCHEMBL288756

SCHEMBL288756

SCHEMBL288756

COc1ccccc1-n1cccc1P(C(C)(C)C)C(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.51
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MGLL Q99685 1/20 0.39
▸ HCAR1 Q9BXC0 1/20 0.39
▸ DRD2 P14416 4/20 0.38
▸ DRD3 P35462 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HTR3E A5X5Y0 1/20 0.37
▸ HTR3B O95264 1/20 0.37
▸ ADRB1 P08588 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ HTR3A P46098 1/20 0.37
▸ HTR6 P50406 1/20 0.37
▸ HTR3D Q70Z44 1/20 0.37
▸ HTR3C Q8WXA8 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29370031 1.00 GAA (0.51) GAAMEN1KMT2ASMN1; SMN2MGLL
SCHEMBL18821837 0.86 GAA (0.50) GAAMEN1KMT2ASMN1; SMN2MGLL
SCHEMBL16449094 0.82 GAA (0.55) GAAMEN1KMT2AMGLLHCAR1
SCHEMBL21104952 0.80 GAA (0.47) GAAMEN1KMT2AMGLLHCAR1
SCHEMBL12391646 0.79 ALDH1A1 (0.40) MEN1KMT2ASMN1; SMN2MGLLHCAR1
SCHEMBL29972265 0.78 GAA (0.51) GAAMEN1KMT2AMGLLHCAR1
SCHEMBL4903300 0.75 PTPN2 (0.32) —
SCHEMBL289208 0.73 ATM (0.40) GAAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL3433008 0.73 GAA (0.60) GAAMEN1KMT2AMGLLHCAR1
SCHEMBL289065 0.73 GAA (0.46) GAAMEN1KMT2ASMN1; SMN2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427468-B2 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PLC (GB) 2025-06-04 — — EP claimed
US-12122788-B2 Process of making CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-10-22 — — US claimed
US-20230399343-A1 PROCESS OF MAKING CFTR MODULATORS VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-12-14 — — US claimed
EP-4267591-A2 ORGANOMETALLIC COMPOUNDS Umicore AG & Co. KG (DE) 2023-11-01 — — EP claimed
CN-116802187-A Organometallic compounds 优米科尔股份公司及两合公司 2023-09-22 — — CN claimed
CN-114957312-A Aryl silicon compound of conjugated olefin and preparation method and application thereof 南京工业大学 2022-08-30 — — CN claimed
WO-2022136049-A2 ORGANOMETALLIC COMPOUNDS UMICORE AG & CO. KG (DE) 2022-06-30 — — WO claimed
EP-2427468-B1 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PLC (GB) 2017-06-14 — — EP claimed
EP-2885294-B1 SYNTHESIS OF AN ANTIVIRAL COMPOUND GILEAD SCIENCES INC (US) 2016-11-30 — — EP claimed
US-8772520-B2 Preparation of a metal complex JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2014-07-08 — — US claimed
US-8759544-B2 Synthesis of an antiviral compound GILEAD SCIENCES, INC. (US) 2014-06-24 — — US claimed
US-20140051867-A1 SYNTHESIS OF AN ANTIVIRAL COMPOUND GILEAD SCIENCES, INC. (US) 2014-02-20 — — US claimed
US-20140051866-A1 SYNTHESIS OF AN ANTIVIRAL COMPOUND GILEAD SCIENCES, INC. (US) 2014-02-20 — — US claimed
US-8314232-B2 Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide GLAXOSMITHKLINE LLC (US) 2012-11-20 — — US claimed
US-20120116109-A1 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2012-05-10 — — US claimed
EP-2427468-A1 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2012-03-14 — — EP claimed
EP-2339918-A1 PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE GlaxoSmithKline LLC (US) 2011-07-06 — — EP claimed
WO-2010128316-A1 PREPARATION OF A METAL COMPLEX JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2010-11-11 — — WO claimed
US-20100081805-A1 Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide EXELIXIS, INC. 2010-04-01 — — US claimed
WO-2010036831-A1 PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE GLAXOSMITHKLINE LLC (US) 2010-04-01 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399343-A1 PROCESS OF MAKING CFTR MODULATORS CFTR, SLC26A4, TMEM109 GAA 775/4885MEN1 2440/4885KMT2A 4522/4885
US-20140051867-A1 SYNTHESIS OF AN ANTIVIRAL COMPOUND EIF2AK2, SARS1, MAVS GAA 257/4885MEN1 3345/4885KMT2A 3920/4885
US-12122788-B2 Process of making CFTR modulators CFTR, SLC26A4, TMEM109 GAA 775/4885MEN1 2440/4885KMT2A 4522/4885
US-20140051866-A1 SYNTHESIS OF AN ANTIVIRAL COMPOUND EIF2AK2, SARS1, MAVS GAA 247/4885MEN1 3111/4885KMT2A 3923/4885
US-20120116109-A1 PREPARATION OF A METAL COMPLEX PDCD1LG2, CD274, PDCD2L GAA 4147/4885MEN1 458/4885KMT2A 1169/4885
US-20100081805-A1 Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide QDPR, CBR3, NQO2 GAA 3658/4885MEN1 1855/4885KMT2A 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.